BMC Geriatrics · Nov 17, 2026
Medication burden and sarcopenia in older adults: a systematic review and meta-analysis
By Li X, Wang Y, Zhang L et al.
Background Medication burden and sarcopenia are common and clinically important concerns in older adults. Although increasing evidence suggests an association between polypharmacy and sarcopenia, previous findings have been inconsistent, and uncertainty remains regarding the influence of medication-burden measures, sarcopenia diagnostic frameworks, and disease stage. This systematic review and meta-analysis aimed to comprehensively evaluate the association between medication burden and sarcopenia in older adults. Methods PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to August 31, 2026. Observational studies involving adults aged ≥ 60 years were eligible if they evaluated overall medication burden, including polypharmacy or medication count, in relation to sarcopenia defined using a recognized diagnostic framework. The primary meta-analysis pooled multivariable-adjusted odds ratios (ORs) for the association between polypharmacy and confirmed sarcopenia. Additional analyses examined crude ORs according to sarcopenia diagnostic framework, mean differences (MDs) in medication count, and crude ORs for probable or possible sarcopenia. Random-effects models with restricted maximum likelihood estimation were used. Methodological quality was assessed using the Joanna Briggs Institute critical appraisal checklist, and certainty of evidence was evaluated by outcome using GRADE. Results Sixteen studies involving 5,679 participants were included. Five studies contributed multivariable-adjusted estimates to the primary meta-analysis. Polypharmacy was significantly associated with higher odds of confirmed sarcopenia (pooled adjusted OR = 2.25, 95% CI 1.43–3.55; p < 0.001), with modest heterogeneity (I² = 31.43%). Leave-one-out analyses and an exploratory restriction to studies defining polypharmacy as ≥ 5 medications supported the direction of the primary association. Across eight studies reporting crude estimates for confirmed sarcopenia, the pooled OR was 2.18 (95% CI 1.51–3.16); no significant difference was detected across sarcopenia diagnostic frameworks (p = 0.33). In contrast, medication count as a continuous measure did not differ significantly between participants with and without sarcopenia (MD = 0.01, 95% CI − 0.62 to 0.64; p = 0.98; I² = 69.97%). Polypharmacy was also associated with probable or possible sarcopenia (crude OR = 1.82, 95% CI 1.29–2.56; p < 0.001; I² = 30.00%). The exploratory Hartung–Knapp 95% CI for this three-study outcome was 0.86–3.84 and included the null value. The certainty of evidence was rated very low for all four quantitative outcomes. Conclusions Polypharmacy was significantly associated with higher odds of sarcopenia in older adults, whereas absolute medication count alone showed no consistent association. The observed relationship was also evident for probable or possible sarcopenia. However, the very low certainty of evidence, predominance of cross-sectional studies, and variation in exposure assessment, diagnostic criteria, and confounding control limit confidence in the effect estimates and preclude causal interpretation. Routine medication information may help identify older adults for further sarcopenia assessment, although this proposed clinical pathway has not been validated. Prospective studies are needed to clarify temporality and assess the effects of medication optimization on muscle-related outcomes.